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A. Endogenous vasoactive peptides 
Since their discovery, endogenous vasoactive peptides have attracted 
considerable interest because of their concerted actions on the heart, vascular smooth 
muscle and kidney, as well as their ability to alter the release of hormones and 
neurotransmitters. Although much information has been obtained regarding their 
vasoconstrictor and mitogenic actions, their involvement in modulating the activity of 
the cardiovascular system under normal conditions has not been fully elucidated. A 
better understanding of their role in the pathogenesis of a variety of diseases such as 
hypertension, artherosclerosis or acute renal failure is required (Nayler, 1990; Masaki 
et al., 1992). The endogenous vasoactive peptides presumably act through a variety of 
mechanisms to control vascular tone and peripheral blood flow (Said, 1983). Some of 
these peptides (such as angiotensin II, vasopressin and neuropeptide Y) are potent 
vasoconstrictors while others (such as atrial natriuretic peptide and bradykinin) are 
vasodilators acting in parallel to maintain homeostasis (Kramer, 1990). The peptides 
are known to be released mostly by endothelial cells to mediate vasoconstriction in 
1 
response to various chemical and physical stimuli (Doherty, 1992). 
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Figure 1 : The renin-angiotensin system ( Redshaw, 1993) 
Angiotensin II is a potent vasoconstrictor acting on smooth muscle and in the 
central nervous system. It is an octapeptide which in vascular smooth muscle acts 
directly via receptors to constrict the arteries and arterioles while in the adrenal cortex 
releases aldosterone which induces sodium and water retention, resulting in a further 
hypertensive effect through increased plasma volume (Redshaw, 1993). It is 
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responsible for the full pressor effect (raise in blood pressure involving 
vasoconstriction) of the renin-angiotensin system (Figure 1) and believed to participate 
in well known events in atherogenesis such as the control of smooth muscle cell growth 
and proliferation (Ambrosioni et al., 1992). 
In the renin-angiotensin system, which correlates renal disease with an increase 
in high blood pressure, a Leu-Val bond connection of a circulating globular protein 
known as angiotensinogen, or renin substrate, is hydrolysed specifically by the aspartic 
acid proteinase, renin, produced in the kidney. This process releases the N-terminal 
decapeptide, angiotensin I, which has no known biological activity. Angiotensin-
converting enzyme (ACE) then cleaves a two amino acid fragment from the C-terminus 
of this decapeptide to give the octapeptide, angiotensin II (Alhenc-Gelas et al., 1990). 
The key factor in the production of angiotensin II (as seen from Figure 1) is the 
angiotensin-converting enzyme (ACE), which warrants further discussion. ACE, a 
glycoprotein widely distributed in mammals, is a membrane-bound enzyme localized 
mainly in endothelial cells (especially pulmonary) with an expression level higher in 
atria than in ventricles (Uratha et al., 1993). ACE is also a well known zinc-containing 
carboxypeptidase that has a central role in blood pressure homeostatis (Studdy et al., 
1989), namely, inactivation of ACE can lower or prevent expected increases in blood 
pressure. As a result, understanding its mode of action and the discovery of enzyme 
specific inhibitors can lead to the development of useful pharmaceutical agents for high 
4 
blood pressure therapy (Ehlers et al., 1989). 
Unfortunately, size (1.3-1.6 kDa) and heavy glycosylation have made_ structure 
elucidation of ACE a very difficult task (Redshaw, 1993). The amino acid sequence 
was not determined until 1988 (Soubrier et al., 1988) after the first inhibitors of ACE 
had been marketed. Even today, ACE structural information is not useful for inhibitor 
design, and the most relevant factors in inhibitor preparation remain a knowledge of the 
enzyme's substrate specificity together with an understanding of the catalytic 
mechanism (Redshaw, 1993). Despite these drawbacks, the fact that there is an 
essential zinc ion in its active site encourages comparison with other zinc 
metalloproteinases. Among them, thermolysin (TLN) (Matthews et al., 1974), is a well 
known zinc-dependent enzyme and its structure has been determined by X-ray 
crystallography. Although the amino acid sequence of thermolysin is not necessarily 
related to the sequence of other zinc-requiring peptidases such as ACE or CPA 
(carboxypeptidase A, another zinc-dependent enzyme) (Christianson et al., 1986), there 
is increasing evidence that the active sites of these zinc enzymes have common features 
(Kester et al., 1977; Cushman et al., 1977; Ondetti et al., 1977). As such, recent X-
ray structures of thermolysin-inhibitor complexes have proven useful in elucidating the 
mode of binding of related zinc peptidases including ACE (Holland et al., 1994; 
Tronrud et al., 1992). Moreover, commercial availability and cost makes thermolysin 
easier to study. Therefore, understanding thermolysin's mode of action can aid better 
5 
understanding of ACE. 
B. Thermolysin 
Thermolysin is a thermostable, zinc-containing endopeptidase isolated from the 
thermophilic bacterium Bacillus thermoproteolyticus (Copie et al., 1990). It has a 
molecular weight of 34,600 and contains 316 residues in its single polypeptide chain 
(Holland et al., 1992). Thermolysin is related to other peptidases such as ACE, 
collagenase, enkephalinase and other neutral endopeptidases, and has been recognized 
to play important roles in cellular and hormonal metabolism (Copie et al., 1990). In 
addition, thermolysin has proven to be an advantageous system for the detailed 
evaluation of protein-ligand binding effects (Morgan et al., 1991). 
The enzyme is particularly suited for studying the mechanism of zinc-promoted 
peptide hydrolysis because a variety of crystallographic, inhibitor, substrate, and 
chemical modification data are available. Importantly, the crystal and solution 
conformations appear to be very similar on the basis of available experimental 
comparisons (Hangauer et al., 1984) and the findings that the crystalline enzyme still 
hydrolyzes peptides. The relevance of the crystal structure (which has been determined 
to 1. 60 angstrom resolution (Holmes et al., 1982)) is further enhanced by the fact that, 
in general, thermolysin changes very little upon binding numerous inhibitors; this 
feature makes thermolysin a good model enzyme for mechanistic studies of zinc 
6 
peptidases (Hangauer et al., 1984). 
The crystal structure of thermolysin together with computer graphics analysis of 
the active site, and the x-ray structure of an N-carboxymethyl dipeptide inhibitor 
(Mozingo et al., 1984) have led to a proposal of its mechanism (Tronrud et al., 1986). 
Tyr 157 
His 231 (Copie et al., 1990) 
Figure 2: Postulated tetrahedral intermediate formed during thermolysin's 
enzymatic action (Presumed hydrogen interactions are drawn 
as dashed lines. Thermolysin's zinc ion is shown coordinated to 
three protein amino acid residues and two substrate ligands). 
As shown in Figure 2 (Tronrud et al., 1986, Fersht, 1985), the protein consists mainly 
of two spherical domains with a deep cleft in the middle, which constitutes the active 
site. In its native state, thermolysin has a single water molecule bound to the zinc ion. 
7 
The aforementioned inhibitor, N-( l-carboxy-3-phenylpropyl)-l-leucyl-l-tryptophan, has 
been observed to bind to thermolysin with the carboxyl group close to leucine 
interacting with the zinc. In addition, the leucyl side chain was found to be required by 
the active site due to its nestled location in the hydrophobic specificity pocket. 
Together with three ligands from the protein (Glu-166, His-146, and His-142), 
the zinc coordination is essentially tetrahedral. As a peptide substrate binds, the 
carbonyl oxygen (previously mentioned) forms a fifth zinc ligand and displaces the 
bound water molecule towards Glu-143. The water molecule, activated by the 
combined influence of Glu-143 and the metal, attacks the carbonyl carbon of the 
substrate forming a tetrahedral intermediate in which two of the oxygens become zinc 
ligands, thus creating a pentacoordinated zinc ion. A proton, accepted by Glu-143 
from the attacking water molecule, is shuttled to the leaving nitrogen, leading to 
cleavage of the scissile bond and displacement of products. In such a mechanism, Glu-
143 performs the dual role of assisting the attack of the water molecule on the carbonyl 
carbon of the peptide bond and also acting as the proton donor to the nitrogen (Fersht, 
1985). 
C. Transition state and enzyme catalysis 
The term transition state (TS) refers to the configuration along the reaction 
coordinate that a specie must pass through on its way to product formation (Figure 3). 
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The transition state corresponds to the highest energy state in the course of a reaction; 
it is a dynamic, reactive and unstable state in which bonds are only partially formed or 
broken. According to transition state theory, the physical entities under consideration 
during a reaction are the reagents, or ground states, and the most unstable species in the 
reaction pathway, the transition state(s). The importance of transition state theory is 
that it relates the rate of a reaction to the difference in Gibbs Free Energy (G) between 
the transition state and the ground state. This is an important consideration when 
comparing the relative reactivities of pairs of substances or the rates of a given reaction 







Figure 3 : Effect of catalyst on reaction pathway. 
Solid line = uncatalyzed 
process 
Dashed line = catalyzed 
process 
Product(s) 
The difference in height on the energy surface between the starting materials 
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and the transition state is the reaction's activation energy (or LlGTs), and is the energy 
barrier that must be overcome before the reactants can convert to product. The higher 
a reaction's activation energy is, the more difficult the path to products. An enzyme, 
however, can speed up a reaction by lowering the activation energy thus providing a 
smaller energy "hill" in the reaction pathway (Bender et al., 1984). Thus, enzymes 
function as catalysts in reactions, meaning that they alter the rate of a reaction without 
themselves undergoing change. The enzyme is able to function as a catalyst by 
converting the substrate into a specific product through formation of a reactive TS. 
One of the enzymes primary functions in its role as the catalyst, however, 















S = substrate 
ES = enzyme substr. complex 
P = products 
EP = enzyme prod. complex 
Figure 4 Energy levels in catalysis vs. normal reaction 
is not its ability to strongly bind the substrate or the product but rather its ability to 
discriminate between substrate, product and the transition state. In 1946 Linus Pauling 
suggested that an enzyme binds more strongly to the transition state than to the 
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reactants or products (Pauling, 1946). When the enzyme captures the transition state, it 
is stabilized and as a result, less energy is needed to access this structure. The energy 
barrier is lowered and the reaction is generally accelerated - often by factors of several 
orders of magnitude in rate (Figure 4). The enzyme's effect is catalytic because the 
products immediately diffuse away from the active site following formation, enabling 
the enzyme to bind and transform new molecules of substrate repeatedly (Lerner et al., 
1988). To provide for the catalytic affinity, interactions between the enzyme and the 
substrate are extensive with a specificity reflected in the transition state (Wolfenden, 
1969). The binding interactions are quite numerous and can include hydrophobic, 
ionic, n-stacking and hydrogen bonding. 
D. Transition State Analogues 
Transition state analogues are molecules designed to exploit and manifest the 
special interactions that distinguish the substrate in the transition state from the 
substrate in the ground state (Jencks, 1966), and can be used to probe differences in 
enzyme binding at various stages in the reaction coordinate rather than to establish 
absolute structures. Pauling predicted that it would be possible to utilize transition state 
analogues as enzyme inhibitors (Pauling, 1946). He predicted that, given a reaction for 
which an enzyme exists, a stable substance might mimic the native, reactive transition 
state in shape and charge. Such a transition state analogue should bind very tightly to 
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the enzyme, inhibiting its catalytic action by filling the binding site at its most 
complementary state and thereby preventing the active site from binding to its true 
substrate (Lerner et al., 1988; Bartlett, 1984). This theory has been validated over the 
last 20 years, as a significant number of compounds have been synthesized that behave 
as TS analogues in just the manner Pauling predicted. An example of the depiction of 
enzyme action is supported by studies that show that stable mimics of transition states 
(such as phosphonates) are held tightly by enzymes that employ the putative mechanism 
(Wolfenden, 1969, 1972, 1991) (Figure 5). In this mechanism, a phosphorus atom has 
been substituted for a reacting carbonyl in the transition state's tetrahedral ensemble, 
yielding a stable compound known as a phosphonate ester. The distribution of charge 
on the phosphonate oxygen atoms of the molecule resembles that of the transition state. 
In addition, the phosphorus-oxygen bonds are about 20 percent longer than ordinary 
carbon-oxygen bonds, which enables the analogue to mimic the elongated bonds of the 
transition state (Lerner et al., 1988). Importantly, phosphorus esters and amides by 
virtue of their sp3 hybridized center, closely resemble the transition state achieved 
during the hydrolysis of certain carbonyl compounds (Hanson et al., 1989). As a 
result, many of these phosphorus-based analogues have been used as enzyme inhibitors 
(Dreyer et al., 1989; McLeod et al., 1991) and as haptens for the production of 
catalytic antibodies (Lerner et al., 1987). 
The arrival of stable TS analogues, conceived to mimic the structure of an 
12 
intermediate in the path of a substrate's transformation to product, have made it 
H 
8- I 8+ 
0 0 )< ".H 
R OR1 
transition state 
~ + HORi_ 
R OH 
phosphonate 
stable transition state analog 
Figure 5: Hydrolysis of ester and phosphonate analog 
possible to examine the degree of enzyme binding/distortion energy, and to probe the 
specificity and selectivity of this interaction. Most TS analogues behave as potent 
inhibitors because, unlike the native substrate, they are not transformed into product 
and remain tightly held in the catalytic domain, thereby inactivating the enzyme. Some 
enzyme inhibitors have been used to study the role of individual enzymes, to 
understand enzyme mechanisms and to aid in the development of pharmacological and 
agricultural agents (Bartlett et al. , 1987). Among them, peptides containing a 
transition state-analogue in place of a hydrolyzing amide bond have received 
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considerable attention. Typically, peptide TS analogues contain a phosphonamidate or 
a sulfonamide moiety (Moree et al., 1993) which show the best resemblance to the 
transition state during the hydrolysis of the amide bond from both a steric and 
electronic point of view (Figure 6). These TS analogues are used in the development 
of protease inhibitors such as thermolysin, renin and pepsin. 
HO o-x 
R NR1R2 
a b C 
(R = alkyl, R
1 
= alkyl, R 
2 
= H, alkyl) 
Figure 6: TS analogues of amide bond hydrolysis. 
E. Phosphorus-Containing TS Analogues as Thermolysin Inhibitors 
Some of the most potent inhibitors of thermolysin are transition state analogues 
which incorporate phosphorus-containing tetrahedral groups capable of binding to the 
active site zinc in a bidentate fashion (Holmquist, 1977; Galardy, 1982). 
Phosphonate, phosphinate, phosphonamidate and phosphoramidate analogues 
(Figure 7) designed to the same transition state show different binding propensity to 
thermolysin (Bartlett et al., 1990). The enhanced binding and inhibitory potency of the 




/ "' R1 R2 
Phosphonate: X = 0, R1 = OR, R2 = alkyl, aryl 
Phosphinate: X = 0, R1 = R2 = alkyl, aryl 
Phosphonamidate: X = 0, R1 = NHR, R2 = alkyl, aryl 
Phosphoramidate: X = 0, R1 = NHR, R2 = OR' 
Figure 7: Phosphorous containing monoacids as TS analogues. 
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amidate (Bartlett et al., 1987). Grobelny and co-workers noted that the binding energy 
difference were due to increased basicity of the phosphonamidate anion (better ligates 
the active site zinc atom), whereas solvation effects were negligible (Grobelny et al., 
1989). 
A well known phosphorus-containing inhibitor used to probe the mechanism of 
thermolysin is phosphoramidon [N-(a-L-rhamnopyranosyloxyhydroxyphosphinyl)-L-
0 COOH N 
I 
H 
Figure 8: Phosphoramidon 
leucyl-L-tryptophan] (Figure 8). This naturally occuring potent inhibitor (K3 = 2.8 x 
10-s M) (Suda et al., 1973), consists of a rhamnose sugar group attached to a leu-tryp 
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moiety through a phosphate P=O (Umezawa et al., 1972). The phosphoramidon-
thermolysin complex was crystallized, and showed monodentate Zn-ligation to one of 
the phosphate oxygens, 2.0 angstroms from the zinc atom, resulting in a tetrahedral 
complex which closely resembles the transition state during the catalytic process 
(Tronrud et al., 1986). Additionally, the crystal structure reaffirmed that the N-
phosphoryl group mimics a hydrated peptide since it was seen that the P-O bonds were 
only slightly longer than the corresponding C-O bonds, and both the phosphoryl group 
and a hydrated peptide are tetrahedral (Hangauer et al., 1984). Interestingly, removal 
of the rhamnose moiety from phosphoramidon resulted in a slightly tighter binding 
inhibition (Komiyama et al., 1975) indicating that the sugar is not essential for 
thermolysin recognition. 
Based on the effectiveness of phosphoramidon as an inhibitor of thermolysin, a 
series of related phosphoramidates and phosphonamidates have been synthesized and 
proved to be potent inhibitors not only of thermolysin, but also of other zinc peptidases 
including carboxypeptidase A, endothelial converting enzyme (ECE) and angiotensin 
converting enzyme (ACE) (Jacobsen et al., 1981; Bigaud et al., 1994). As an 
example, Bertenshaw truncated the phosphoramidon structure in an attempt to inhibit 
ECE, and the study found that the sugar moiety was not essential for anti-ECE activity 
(Bertenshaw et al., 1993). Previous studies (Jacobsen et al., 1981; Bigaud et al., 1994) 
also reaffirmed that the rhamnose moiety was of very little importance for the 
o·-,0,/o 
"-"/ 




X =CH2 ,0 
Bertenshaw et al., 1993. 
Figure 9: Bertenshaw's Truncated Version of Phosphoramidon 
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inhibition of ACE or ECE, whereas the phosphoryl group of phosphoramidon was an 
absolute requirement. Furthermore, the tryptophan residue of phosphoramidon 
appeared to be important for the ECE inhibition while thermolysin inhibition seemed to 
depend greatly on the leucine residue. It was concluded that in vivo ECE and 
themolysin differ only in the way they recognize phosphoramidon. 
F. Statement of the Problem 
Phosphorus-containing analogues have made significant contributions to our 
understanding of TS structure; however, several drawbacks to their application 
(resulting in deficits in current understanding) do remain. Some of these drawbacks 
include; (A) a lack of an essential hydrogen-bonding or salvation interaction in some 
phosphonates and phosphinates leaves them ineffectual, (B) instability to acid for many 
phosphonamidates, and (C) when used as haptens, fail to result in antibodies with 
substantial catalytic activity suggesting that key elements in binding amidases may be 
absent in phosphonamidates (McLeod et al., 1991). 
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Despite these drawbacks, phosphorus-containing analogues do offer useful 
advantages. Certain phosphorus esters and amides, by virtue of their sp' hybridized 
center, closely resemble the transition state achieved during the hydrolysis of certain 
carbonyl compounds. Another important advantage is the use of 31 P NMR, a sensitive 
nucleus, capable of revealing highly diagnostic chemical and biochemical information. 
In addition, the use of x-ray, as in the case of the x-ray crystal structure of a 
thermolysin-phosphoramidate transition state analog, has given tremendous insight into 
the TS-protein interaction (Tronrud et al., 1986). Doubtless, the systematic design and 
use of phosphorus-containing analogues will remain a promising path toward more 
specific and potent inhibitors (or probes) of protein structure and function. 
In this study, our aim is to enhance our understanding of the utility of 
phosphorus-containing transition state analogues by attempting to synthesize a 
tripeptide-based TS analogue that resembles phosphoramidon. The chosen transition 
state analogue could be used to suppress the enzyme thermolysin, thus furthering our 
understanding of the requirements of zinc-containing enzymes. 
The project's concept is based on Bertenshaw' s truncated version of 
phosphoramidon (Figure 9), and the discovery that the sugar moiety has very little 
importance in the inhibition of the enzyme. Therefore, the main focus of the project is 
centered on synthesizing a transition state analogue of phosphoramidon without the 
sugar group. First, the tripeptide acetyl-l/d-phenylglycine-l-leucine-l-tryptophan, 
18 
methyl ester was selected to serve as a natural substrate for this transition state 
analogue, and was synthesized as the "S" and "R" isomeric forms 9a and 9b. This 
tripeptide closely resembles phosphoramidon' s peptide sequence with the sole exception 
of the substitution by an N-acetyl phenylglycine group. The acetyl group was elected 
as an end cap for the amino group to better stimulate the carboxamide junction of an 
extended peptide chain. Phenylglycine was chosen because the enantiomers of the 2-
phenyl phosphonate amino acid analogue are easily prepared, and the recent report by 
Bertenshaw revealed that the benzyl and phenoxy phosphonate analogues of this 
tripeptide showed parallel biological activity to phosphoramidon (Bertenshaw et al., 
1993). In our case, we synthesized both "S" and "R" isomers of the tripeptide to serve 
as the natural and unnatural models for the TS analogue - which when synthesized, are 
racemic at the a-phosphorus center. [Note: the "R" configuration for a phosphonate a 
center corresponds to the amino acid "S" configuration]. We selected the l-leu-l-tryp 
dipeptide to maintain consistency with phosphoramidon's structure. More importantly 
however, the leucyl moiety was used due to its importance in known binding affinity to 
zinc-containing enzymes (as previously mentioned, the active site of thermolysin 
requires leucine in its hydrophobic pocket). 
Once we obtained these native tripeptides, we will attempted the synthesis of the 
phosphono-substituted tripeptide. In the past, phosphorus-containing peptides have 
been prepared by conversion of a phosphono-derivative of an amino acid to a methyl 
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phosphonochloridate, and condensed with either the amine moiety of a flanking amino 
acid (Khatri et al., 1980; Bartlett et al., 1986; Bertenshaw et al.; 1993), or an alcohol 
(Bartlett et al., 1990; Sampson et al., 1991). Subsequent hydrolysis of the phosphorus 
methyl ester affords the phosphonic acid. Yuan and Chen (1990, 1992) reported a 
three component, one pot Pudovik synthesis of a-substituted, 
dimethylphosphonamidates from simple starting materials. Phosphorylation of 
dipeptide amines under basic conditions or with phase transfer catalysts can be 
conducted (Ma et al., 1992; Li et al., 1992). 
In our case, we will first attempt the preparation of optically active 
phosphonamidate diastereomers 13 and 14 by an imine Pudovik reaction (Arbusov et 
al., 1978; Zon, 1981). Although more inventive approaches exist, this strategy permits 
for: a) rapid acquisition of the materials, b) variation in the amino acid R group, and c) 
inexpensive starting materials. Following acquisition of 13 and 14, the next steps 
attempts to modify these intermediates into compounds suitable for coupling to the 
dipeptide l-leu-l-tryp, methyl ester 8 to obtain the desired phosphono-substituted 
tripeptide. The attempted modifications included thionation, acetylation, hydrolysis, 
dealkylation and chlorination. These transformations resulted in the formation of a 
racemic salt representing a phosphorus analogue of acetyl-phenylglycine. The salt was 
the subject of further investigations in an effort to couple it to the deprotected dipeptide 
to yield the expected phosphono-substituted peptide. 
20 
This thesis will describe (a) the preparation of the native tripeptide acetyl-
phenylglycine-l-leucine-l-tryptophan, methyl ester synthesized as the "S" and "R" 
isomers (Figure 10); (b) the preparation of the phosphorus analogue of acetyl-
phenylglycine (Figure 11), and (c) attempts for the preparation of the phosphorus-
containing tripeptide (Figure 12). 





Figure 11 : Phosphorus analogue of acetyl-phenylglycine 
21 
Figure 12 : Phosphorus substitute tripeptide (TS analogue) 
CHAPTER II 
RESULTS AND DISCUSSION 
The specific aim of the project is to synthesize a phosphoramidon-like transition 
state analogue capable of strongly binding thermolysin. This analogue could also 
improve our understanding of the effect that a sp3-hybridized phosphorus center 
substituting for a peptide carbonyl has on the conformation and dynamics of a peptide 
backbone (this can be achieved through the use of NMR or molecular modeling). 
Additionally, if active against the enzyme thermolysin, it could be used to more 
precisely probe the requirements of zinc protease inhibition. 
The first goal toward the preparation of the TS analogue started with the 
synthesis of native tripeptides acetyl-d/l-phenylglycine-l-leucine-l-tryptophan, methyl 
ester 9a and 9b (Part A). We selected this tripeptide because it resembles 
phosphoramidon' s peptide sequence and connectivity except for the sugar group 
rhamnose, which was shown to have a minor role in the inhibition of the enzyme. The 
native tripeptide is intended to serve both as a model for comparison of enzyme 
interaction and as a synthetic entry for the phosphonate transition state analogue. The 
amino acids used were l-phenylglycine, l-leucine and l-tryptophan, methyl ester and 
22 
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were appropriately protected prior to coupling. Both tripeptides were successfully 
synthesized by conventional solution methods using DCC as the amide.:.forming 
coupling reagent. Following their successful acquisition, we also attempted to 
synthesize the native tripeptides by solid phase peptide synthesis techniques, however, 
without success. 
The second goal of the project was the preparation of a phosphorus analogue of 
acetyl-phenylglycine (Part B). This analogue will be reacted with the dipeptide l-leu-l-
tryp, methyl ester 8 to obtain the phosphono-substituted tripeptide 24. The synthesis 
for the analogue started with preparation of optically active phosphonamidate 
diastereomers 13 and 14 which could be later separated into their corresponding 
isomers. Following their acquisition, we tried to separate each diastereomer pair by 
column chromatography and GC but to date, both techniques have been unsuccessful. 
Final steps attempted to modify 13 and 14 into compounds suitable for coupling 
with the dipeptide l-leu-l-tryp, methyl ester 8 to obtain the phosphorus-containing TS 
analogue 24 (Part C). Attempted modifications included thionation, acetylation, 
hydrolysis, dealkylation and chlorination. 
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Part A: Synthesis of acetyl-l-phenylglycine-l-leucine-1-tryptophan. methyl ester: the 
native tripeptide. 
The first goal of the project was the synthesis of the native tripeptide 9a as both 
a model and a synthetic entry toward the preparation of the phosphonate precursor. 
The three amino acids used to construct the tripeptide were l-phenylglycine, l-leucine 
and l-tryptophan methyl ester and were end protected at the amine terminus prior to 
coupling when necessary. 
Commercially available l-phenylglycine 1 was successfully blocked as the 
acetamide using lM NaOH and (CH3CO)2O at O °C, to provide N-acetyl-/-
phenylglycine 2 in a 74% yield (Eqn. 1) (Bodanszky et al., 1984). These reaction 








L-Phenylglycine N -Acetyl-L-Phenylglycine 
1 2 
(1) 
under neutral or acidic conditions failed. Under basic conditions, the reaction 
proceeded rapidly, had the highest yield, and the product was easily recrystallized from 
water. The acetyl group was selected as an end cap due to its resemblance to a native 
peptide amide bond and the ease of identification by NMR. Evidence of acetyl-l-
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phenylglycine 2 formation ic;; supported by the presence of two carbonyl peaks in 13C 
NMR (at 8 169.2 and 172.3 ppm) and a singlet near 2.0 ppm in the 1H NMR indicative 
of the CH3C(O) moiety. Additionally, the 192-194 °c melting point was close to the 
literature value (190-192 °C) (Hongo et al., 1981). 
The amine terminus of l-leucine was blocked next in preparation for coupling to 
tryptophan. l-Leucine 3 was reacted with benzyl chloroformate (Cbz-Cl) using 
Schotten-Bauman conditions (CH2Cl2 , aqueous NaHCO3 , RT), to yield N-Cbz-l-leucine 
4 in a 75% yield (Eqn. 2). A thick, light-yellow oil was formed after Kugelrohr 










Compound 4 did not solidify even after prolonged storage in the freezer. The 13C 
NMR spectrum shows the requisite Cbz-carbonyl and the 1H NMR indicates the 
addition of a benzyl methylene group (8 5.24 ppm, 2H) and five aromatic protons in 
the correct integration. These data were sufficient evidence to support that the correct 
product was formed despite the difference in physical composition. 
Having these two amino acids securely end blocked, preparation of the dipeptide 
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was conducted next. First. !-tryptophan. methyl ester hydrochloride 5 wa<; convened to 
the primary amine using triethylamine (TEA) in THF at room temperature to give l-



















L-Tryptophan, Methyl Ester 
6 
l CBZ-L-Leucine 4 DCC I CH2Cl2 
ooc 
CBZ-L-Leucine-L-Tryptophan, Methyl Ester 
7 
Scheme 1: Synthesis of l-leucyl-1-tryptophan, methyl ester 8 
imide (DCC) (anhydrous CH2Cl2, 0 °C), to form the activated complex which 
undergoes coupling with 6 to form the Cbz dipeptide 7 in 77% yield. The crude 
dipeptide was obtained initially in the form of a viscous oil but after purification by 
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flash chromatography. a white solid was obtained. The 1H NMR spectrum shows the 
correct integration of protons including a 6 H containing doublet at 0.87 ppm from the 
gem dimethyl of Cbz-l-leucine, the methyl ester singlet (3 H), benzyl-Cbz methylene 
(as a doublet), and all the aromatic protons. The 13C NMR is also consistent with the 
structure as evidenced by the two carbonyl groups, as are other physical data including 
rotation and melting point (Shiba et al., 197 4). 
The next stage in the synthesis was to append a phenylglycine to the leu-tryp 
dipeptide. To accomplish this, deprotection via hydrogenolysis of the Cbz group was 
first conducted using 10 % Pd/C in ethanol under balloon hydrogen pressure to give l-
leucyl-l-tryptophan, methyl ester 8. However, this compound was short lived and had 
to be immediately reacted in the next step within 24 h due to [potential] cyclization. 
NMR spectra were therefore taken on the protected dipeptide 7 and compared to that of 
Cbz-/-leucine and l-tryptophan, methyl ester hydrochloride. All the correct signals are 
present in the 1H NMR and the amine N-H peaks appear as expected: doublets for the 
two amine groups in the backbone owing to amide rotomers and a singlet for the 
tryptophan indole amine. Additionally, 13C NMR shows three carbonyl peaks, the 
aromatic ring carbon atoms, and also accounts for the remaining carbon atoms. 
The last step in this synthetic sequence involved coupling of acetyl-/-
phenylglycine 2a or acetyl-d-phenylglycine 2b to the deprotected dipeptide 8 to 
produce the native tripeptides 9a and 9b (Scheme 2; shown for the l isomer). The 
28 
synthesis was achieved by simultaneously combining equimolar amounts of 2a or 2b 
and DCC at 0 °C for 30-40 minutes to form the corresponding activated complex, 
followed by the addition of the deprotected dipeptide 8. 
0 
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Acetyl-L-Phenylglycine-L-leucine-L-Tryptophan, Methyl Ester 
9a 
Scheme 2: Synthesis of acetyl-L-phenylglycine-L-leucine-L-tryptophan, methyl ester 9a 
In this way, addition of the carboxylic acid to the diimide first allowed the formation of 
the intermediate activated O-acylisourea which undergoes nucleophilic substitution by 
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the amme from the deprotected dipeptide to yield the tripeptide product 9a or 9b 
(bearing a newly formed amide linkage) and dicyclohexylurea as side · product 
(Streitweiser and Heathcock, 1985). The solvent for this reaction was anhydrous 
CH2Cl2 since dicyclohexylurea (DCU) - the coupling by-product of the reaction is 
insoluble and can precipitate out for easy removal by filtration. However, the 1H NMR 
showed that a significant amount of DCU was still present in the crude mixture 
following filtration, and trituration with hot CH2Cl2 was necessary to remove the DCU. 
Repeated recrystallizations from CH2Cl2 and diethyl ether were also needed to obtain 
the pure tripeptide. The large number of purification procedures reduced the overall 
recovery but tripeptide 9a (Scheme 2) was still obtained in a 52 % yield. Similarly, 
tripeptide 9b (Scheme 3) was obtained in a 49% yield starting with d-acetyl 
phenylglycine. Both compounds are in the form of white powders, with similar 
melting points. The 1H NMR of both S ([) and R (d) isomers is consistent with the 
proposed structure. The 13C NMR shows the requisite four carbonyl peaks, twelve 
unique aromatic peaks and ten aliphatics. When comparing the 1H NMR and 13C NMR 
spectra of both diastereomers, they appear nearly identical as would be expected. Our 
preliminary spectral examination did not reveal any distinct differences that could be 
attributed to the sole change in chirality at the phenylglycine a-center. The spectra 
show similar peaks with similar chemical shifts throughout, especially for the 












L-Leucine-L-Tryptophan, Methyl Ester 
8 
Acetyl-D-Phenylglycine-L-leucine-L-Tryptophan, Methyl Ester 
9b 
Scheme 3: Synthesis of Acetyl-D-phenylglycine-L-leucine-L-tryptophan methyl ester 9b 
strong peak intensities along the diagonal and the cross peaks that indicate coupling 
between the Trp-Trp 1H's, OCH3-Trp 
1H's and Leu-Leu 1H's, consistent with the 
proposed structure. 
Having obtained the native tripeptides, the synthesis of a terminal phosphono-
tripeptide isostere was next undertaken. However, since the insertion of the 
phosphonamidate moiety into a peptide backbone is rather difficult, a three-tier 
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approach was designed. The challenge was to first synthesize pairs of optically activf' 
phosphonamidate ester diastereomers, followed by their modification into suitable acid 
derivatives, and finally coupling with the unprotected dipeptide 8 to form the 
phosphorus-containing tripeptide. 
Part B: Synthesis of phosphonamidate compounds. 
Synthesis of the phosphonamidate analogues of phenylglycine diastereomers was 
first attempted by an asymmetric induction method, described initially by Gilmore and 
McBride, 1972. In this synthesis, the Schiff base between (S}-(-)-a-methylbenzylamine 
and benzaldehyde was prepared, followed by addition of diethylphosphite or dimethyl 
phosphite to the pre-formed imine to give diastereomeric mixtures of 13 (methyl esters) 
or 14 (ethyl esters) in 86.0% and 89.3%, respectively (Zon, 1981) (Scheme 4). 
Separation of each diastereomer pair was attempted by column chromatography and GC 
but to date, both techniques have been unable to resolve the stereoisomers. Each of the 
product sets (13 or 14) contains two centers of asymmetry with the a-methyl benzylic 
center established as the S configuration thereby leading to 2 stereoisomers. The 1H 
and 13C NMR indicate the correct products as a diastereomeric mixture although the 
NMR signals appear as duplicates throughout, making the spectra quite complex. In 
order to confirm the structures of diastereomers 13 and 14, two alternate procedures 
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were used to synthesize them: one employing K:CO: (Lekszko et al.. 1977) and another 
using MgSO4 (Suarez, 1994) as dessicant to promote formation of the Schiff bases. 
The 1H, 13C, 31 P spectral data along with melting points for the products from these 
procedures were compared to the spectra and melting points from the first procedure 
and were found to be identical. However, the yields from the last two procedures were 
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Scheme 4: Synthesis of (R,S)-dimethyl and diethyl-N-(S)-(methylbenzyl)-
-aminobenzy l phosphonate 
33 
the phosphonamidate diastereomers do form in each case. and the original procedure 
would be preferable (based on yield) for further study. 
The next step attempted to transform the diastereomer mixture of 
phosphonamidate compounds 13 into phosphonamidothioates by replacing the 
phosphoryl (P=O) oxygen with a sulfur atom (Eqn. 3) (Table 1). It was hoped that the 
less polar nature of the P=S linkage would afford a more easily separable mixture of 
the diastereomers, and permit progress of the synthesis at the same time. Several 
procedures were attempted to exchange P=O for a P=S. First, S8 with toluene and 
stirring for 48 hours was tried but thin layer chromatography did not indicate formation 
of any new compounds, and showed that almost all of the starting material remained. 
Lawesson's reagent (2,4-bis( 4-methoxyphenyl)-1,3-dithia-2 ,4-diphosphetane-2, 4-
disulfide), which has been shown to exchange a P=O for a P=S, was tried next (Cava 
et al., 1985). Starting material and Lawesson' s reagent (0.5 equiv.) were dissolved in 
0~ ,..,,...oCH3 S3 .. S~ ,..,,...OCH3 
(:H3 ~-OCH3 CH ~-ocH _ 3 _ 3 -
uru Lawesson's uru (3) reagent 
P~SJQ "' 
13 15 
toluene and brought to reflux for 2-3 hours. TLC indicated numerous spots, and after 
purification by column chromatogaphy only starting material and Lawesson's by-
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products were recovered. The majority of the by-products showed two SCH. signal<; 
between 2-4 ppm and a OCH3 singlet at 3.9 ppm corresponding to the anisyl group of 
(MeS)2P(S)Ar. The phenyl protons were split into a 2:2 quartet pattern, 1 ppm apart, 
and the 31P NMR gave one signal at 84.2 ppm corresponding to the P=S linkage of 
these by-products. Additionally, by-products formed from the (CH3CH2O)2P(O)R 
phosphonamidate failed to show the ethoxy signals expected from the diethyl esters. 
Table 1: Summary of Sulfurization Conditions 
Starting Reaction Expected Observations 
material conditions products 
13 S8, toluene, 48 hr P=S TLC: only sm 
14 
13 Lawesson, reflux, P=S Lawesson's by-
14 toluene, purif. by column products isolated 
13 Lawesson, reflux, P=S sm + Lawesson' s 
toluene, purif. by extraction by-prod. isloated 
14 P 4S 10, CH2Cl2, reflux P=S sm recovered 
With the thought that phosphorus ester hydrolysis may have accompanied P=O/P=S 
exchange, an extraction procedure was attempted in place of the column. After reflux, 
the solution was diluted in diethyl ether, washed with 10 % HCl, neutralized with 
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NaOH and washed with ether. However. Lawesson's by-products similar to those 
described before were again obtained. 
In an effort to eliminate additional impurities, Lawesson's reagent was 
recrystallized and toluene was redistilled. All the reactions were repeated under the 
same conditions, but the result~ remained dissapointing; either starting material or 
Lawesson's by-products were collected. Combinations of reactions using recrystallized 
Lawesson's with regular toluene or purified toluene with regular Lawesson's were tried 
and were unsuccessful. A final trial to conduct a P-O/P=S exchange used P4S10 in 
CH2Cl2 and overnight reflux. After recrystallization from absolute ethanol, 
31 P NMR 
indicated starting material. It is not yet fully understood why all of these reactions 
failed to give the desired product. Perhaps combined steric factors from the phenyl and 
phosphorus ester methoxy or ethoxy groups are a problem or intramolecular hydrogen 
bonding between the amine proton and the oxygen weakens one of the P-O bonds, 
making the replacement slower. 
While still searching for a good sulfurization reagent or different conditions, our 
alternative approach sought to acetylate the amine group of either compounds 13 and 14 
(Eqn. 4) (Table 2). The acetyl group was chosen as a blocking group since this 
truncated amide linkage resembles the native peptide structure. The intent at this point 
was that after successfully blocking the amine group to form 16, debenzylation would 
leave the desired acetyl-NH-phosphonamidothioate moiety. This fragment would be 
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coupled with the unprotected dipeptide 8 using DCC methodology to obtain the 
phosphorylated tripeptide. 
Initial acetylation attempts used acetic anhydride, TEA, DMAP. pyridine 
conditions at room temperature overnight or at reflux for 1-2 hours. In each case, thin 





- - - -- - - -u~u 3) CBZ-Cl., uiu (4) H ~ 4) TFAA ~ 
13 5) Ac-Cl 16 
1), 5) R =CH3C(O) 
2) R=HC(O) 
3) R=Cbz 
4) R =CF3C(O) 
layer chromatography showed that a majority of the starting material was still present 
after stirring overnight or after refluxing for up to 3 hours. Workup consisted of 
several washings with 0.50 M cupric sulfate to remove the pyridine. For all trials, 
1HNMR of the crude mixture did not indicate the expected product. The CH3 singlet 
from the acetyl group at 2.0 ppm was not seen. In some cases, extra peaks (not seen 
before) appeared between 5-6 ppm and indicated possible decomposition or elimination 
pathways. In other cases, all the peaks between 3-4 ppm (from the starting material) 
disappeared entirely. Workup was changed from washing with cupric sulfate solution 
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to removal of pyridine on the rotary evaporator followed by column chromatographv. 
Mixtures of starting material with pyridine and different by-products similar to those 
described above were collected. Since acetylation conditions failed to give the desired 
product the reactivity of compound 13 was in question and new routes were considered 
(Eqn. 4). A mixture of formic acid (catalytic), acetic anhydride and overnight reflux 
were tried, but thin layer chromatography again indicated only the presence of starting 
material. 
Table 2 : Summary of Acetylation Conditions 
Starting Reaction Expected Observations 
material conditions products 
13 Ac20, TEA, RT N-Ac brown tar 
14 CH2Cl2, DMAP 
13 HCOOH, Ac20 N-HC(O) TLC: only sm; 
reflux 24 hr rxn didn't occur 
13 TFA, CHCl3, RT N-Ac TLC: only sm; 
then reflux 3 hr rxn didn't occur 
13 Acetyl-Cl, RT N-Ac TLC: only sm 
Protection of the amine moiety of 13 with a Cbz was tried next (CBZ-Cl, 
toluene/NaHC03) (Eqn. 4). After stirring for 2 hours at room temperature only 
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starting material and Cbz-CI were present on thin layer chromatography plate. Since a 
biphasic system was used and the starting material was partially soluble in water, 
probably the starting material was in the aqueous layer, and did not react well with 
Cbz-Cl. A small amount of soap or tetrabutylammonium bromide were added as phase 
transfer catalysts, but after stirring overnight at room temperature, thin layer 
chromatography indicated that starting material, Cbz-Cl and benzyl alcohol remained 
(from the decomposition of Cbz-Cl). Trifluoroacetic anhydride in CHCl3 at room 
temperature conditions was tried next in an attempt to increase the acetylation reactivity 
but this reaction also failed to produce the product as evidenced by thin layer 
chromatography. Even after reflux was applied for 3 hours, the amount of product did 
not increase. The last attempt at acylation employed acetyl chloride which also failed 
to produce the desired product. 
For all the failed acetylation reactions it is believed that the main reason this is 
such a difficult reaction is due to the overall geometry of the molecule. The two 
phenyl groups along with the phosphonate moiety are large enough to sterically hinder 
the attack on the reagent by the amino NH group. The acetylating reagents probably 
have a difficult time channeling between these sterically congested groups in order to 
reach the amino group and react with it. With this in mind, the next approach was to 
change one end of the molecule and create a less crowded system. 
Benzylamine was chosen to replace (S)-(-)-a-methylbenzylamine in the synthesis 
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of phosphonamidate diastereomers 19a and 19b thus eliminating one chiral center and a 
methyl group. The failure of the chiral auxiliary sequence convinced us to aiter our 
strategy. All the acetylation reactions were repeated under the conditions previously 
described and the results were still negative. Only starting material was seen on TLC 
and 1H NMR. This proved that a) the a-methyl group in 13 or 14 did not sterically 
hinder the acetylation since the reaction failed even in the group's absence and, b) even 









Scheme 5: Synthesis of (R,S)-dimethyl-N-benzyl-aminobenzyl phosphonate. 
prior amine protection sequences we hoped to achieve a resolvable diastereomer pair as 
a benefit. Our alternative approach then was to remove the N- benzyl group to obtain a 
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smaller molecule at the amine end which would have a greater chance at acetylation 
(Eqn. 5). The primary amine 20 was successfully obtained in a 91 % yield by 
hydrogenolysis of 13 using 20% Pd/C and 1-2 eq. TFA in the Paar hydrogenator (40 
psi). Initially, 10% Pd/C at balloon pressure followed by 10% Pd/C and 40 psi were 
tried, but the reaction showed a significant amount of starting material even after 16 h. 
Increasing the Pd catalyst concentration to 20% reduced the amount of unreacted 
starting material left after 16 h, but the reaction remained incomplete. When 1-1.5 or 
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at ambient pressure. After purification by column chromatography, 1H NMR shows 
the broad amine peak, 2 pairs of doublets from the 2 OCH3 groups, a doublet from the 
chiral C-H and the phenyl protons with the correct integration. Additionally, 13C NMR 
spectra confirmed the structure through chemical shifts and the correct number of 
carbon absorbencies. 
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The primary amine of 20 was acetylated next using 2 eq of acetyl chloride in 
CH2Cl2 at room temperature for 2-3 h (Eqn. 6). Following workup and 
recrystallization from CHC13/pet ether, the N-acetyl derivative 21 was obtained in a 
51.3% yield. The 1H NMR shows the acetyl CH3 at 1.93 ppm, the 2 pairs of doublets 
from the methoxy groups and the chiral H which now shifted to 5.5 ppm from 4.27 











Although the removal of the a-methylbenzyl group reduced our opportunities 
for a chiral synthesis, the scheme could be advanced. Having successfully synthesized 
21, the next step involved hydrolysis of one of its methyl esters to obtain the target 23. 
Twelve different procedures were tried unsuccessfully (Table 3) including IM NaOH 
(1, 1.2, 1.5, 2.0 eq) Nal (Morita et al., 1978), TMS-Br (Schmidt, 1981; McKenna et 
al., 1979), PEX, (Bu)4NOH, LiOH, at room temperature or at reflux. Either no 
reaction, 'partial' (both methoxy peaks are seen but one is smaller than the other) or 
complete hydrolysis of both esters takes place after aqueous workup (in the case of 
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Table 3: Summary of Hydrolysis Conditions 
Reaction Expected Observations 
conditions products 
lM NaOH, leq, reflux 23 starting material 
lM NaOH, l.2eq, RT to reflux 23 "partial hydrolysis" 
lM NaOH, 1.5 eq, reflux 23 diacid 
lMNaOH, 1.5 eq, RT to reflux, 48hr 23 diacid 
lMNaOH, 2eq RT(8h) to reflux (4h) 23 diacd 
Nal, leq, RT 23 starting material 
Nal, leq + lxtal l2 RT 23 starting material 
Nal, 2eq, RT 23 starting material 
TMS-Br, leg, RT 23 diacid 
LiOH, leq, RT to reflux 23 starting material 
2N NaOH, 0.5eq, RT 23 starting material 
2N NaOH, 1 eq 23 diacid 
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and allowed to proceed for 12-48 h). When this was first observed. extra care was 
given in the extraction step, by reducing the strength of the acid (from 20% HCl to 15, 
10 and 5 % ) . It is important to mention that this reaction worked well on the sterically 
more demanding compound 13 (Eqn. 11). The hydrolysis of 13 was conducted with 1 
eq of lM NaOH in ethanol with reflux for 5 hours. After aqueous workup with 
20%HC1 and one recrystallization, the pure product was obtained in a 74% yield. This 
reaction worked so well in fact, that we were quite confident that it would work on the 
smaller compound 21. However, after many attempts and careful extraction procedures 
the reaction failed to give the desired product 23 (Eqn. 7). It is not fully understood 
why the reaction leads to other products since it worked consistently on 13 under the 
same conditions. One reason for the poor isolation of 23 could be the aqueous workup 
where enough water pushes the reaction toward diacid formation. With this in mind, 
the next approach was to isolate the phosphonate salt which formes prior to workup 
(Eqn. 8). This suggests that the monoacid does form but it is in the form of a salt 
which is unstable to the aqueous workup. The phosphonate salt monoester 22 was 
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layer chromatography indicated consumption of the starting material (Eqn. 8). The 1H 
NMR shows the acetyl singlet and one doublet at 3. 7 ppm from the remaining inethoxy 
group, a doublet from the chiral H and the phenyl protons with the correct integration. 
Most importantly, 31P NMR shows a singlet at 17.9 ppm, - approximately a 7 ppm 
shift upfield from 21. Coupling between the salt and the deprotected dipeptide 8 was 
attempted in an effort to obtain the phosphorus-containing tripeptide 24. The reaction 
was tried several times, using equimolar amounts of salt, deprotected dipeptide and 1,3 













1 eq, TEA 
(9) 
The reaction was run at O °C for 5 hand allowed to proceed to room temperature. After 
30 h, 1H NMR indicated only dipeptide and DCU. The reaction was repeated using 
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equ1moiar amounts of salt. 1.3 diisopropylcarbodiimide and trifluoroacetic acid (to 
restore the protonated form of the acid) with two equivalents of deprotected d1peptide 
and DMF /THF as a solvent. After 30 h however, 1H NMR indicated decomposed 
dipeptide. This reaction was abandoned and efforts were shifted toward converting the 
phosphorus acid salt 22 to a phosphoryl chloride 25 (Eqn. 10) which would then be 
coupled to the amine of a deprotected dipeptide (Table 4). 
Oxalyl chloride, thionyl chloride (Musiol et al, 1994; Bhongle et al., 1987; 
Camp et al., 1992), PC13 and POC13 were tried as chlorinating agents in 1, 1.5 and 2 
eq. for the formation of phosphoryl chloride. For reactions with oxalyl chloride, 0.1 
eq of DMF was used as recomended for the production of acid chlorides (Musiol et al, 
1994). All reactions were unsuccessful and only starting material was isolated for 
reactions employing oxalyl-Cl, thionyl-Cl and POC13 • Decomposition of starting 
material took place when PC13 was used. 
0 n-Na + ~p(_~ 
~ ¥~~ OCH3 
CH3-C-N ~ I 
22 ~ 
oxalyl-Cl, leg ► 
(cat)DMF, RT 
thionyl-Cl, leg, RT ► 
thionyl-Cl, 2eg, RT► 
PCl3, l.5eq, RT 
POCl3, l.5eq, RT,_ 
0~ /Cl p 
o ~ "-OCH3 





Table 4: Summary of Chlorination Conditions 
Starting Reaction Expected Observations 
material conditions products 
22 oxalyl-Cl, 1 eq (cat)DMF, RT P(O)-Cl 25 starting material 
22 thionyl-Cl, 1 eq RT P(O)-Cl 25 starting material 
22 thionyl-Cl, 2 eq, RT P(O)-Cl 25 starting material 
22 PCl3, 1.5 eq, RT P(O)-Cl 25 starting material 
22 POCl3, 1.5 eq, RT P(O)-CI 25 starting material 
In addition to sulfuration and acetylation reactions, also conducted with 13 and 
14, included the hydrolysis of the phosphorus methyl ester of 13. A solution of 13 





from water were used to obtain the mono methyl ester 26 in 74 % yield. The 1H NMR 
shows 3 pairs of doublets: one from the aliphatic CH3 , one from the P-OCH3 , and one 
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due to the a-CH phosphoryl. In addition. a quartet from the CH(CH,) on the second 
chiral center is also seen. The 13C NMR shows the four aliphatic and twelve aromatic 
peaks as expected. The 31P NMR has two peaks appearing at 12.36 and 12.57 ppm in a 
1:3 ratio representing the diastereomer pair. Coupling between 26 and 8 (deprotected 
dipeptide Leu-Trp) was tried next as an attempt at obtaining a phosphorus-containing 
peptide 24 (Eqn. 12). 1,3 Diisopropylcarbodiimide or DCC were tried as coupling 
reagents. DMF had to be used as a solvent due to the poor solubility of 26 in any other 
organic solvent. The reactions were conducted at O °C for 5-7 h and continued at RT 





Part C: Solid phase peptide synthesis. 
In parallel studies, we also attempted to synthesize the tripeptide 9a by solid phase 
peptide synhesis. This is a faster method currently used mainly for the preparation of 
large peptides. Our approach involved the use of 9-fluorenylmethyl chloroformate 
(FMOC) blocked amino acids supported on a p-alkoxybenzylalcohol resin (Wang resin) 
or Cbz blocked amino acids supported on a Merrifield resin (1 % crosslinked 
polystyrene - divinylbenzene). However, before the synthesis of 9a was attempted, we 
first tried to synthesize the tripeptide Leu-Leu-Leu as a simple model. 
For the FMOC blocked amino acids with p-alkoxybenzylalcohol resin method 
Resin--OCH2-0CH20H 
Scheme 6: Chlorination of the resin. 
Fh JP, CX4 RT 
Cliieli, 24h 
Resin -OCH2o--O-CH2- Cl 
the following outline was used: a) chlorination of the resin with Ph3P and CC14 
(Scheme 6); b) conversion of FMOC-Leu to the cesium (Cs) salt; c) coupling of 
FMOC-Leu-Cs salt to the chlorinated resin via Nal; d) deprotection of FMOC group by 
cyclohexylamine/DMF, followed by coupling with FMOC-Leu via DCC; e) repetition 
of step d) followed by ninhydrin test. 
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Initially. we attempted to chlorinate the resin (p-alkoxyhenzylalcohol) usmg 
eq of Ph3P and 2 eq of CC14 per gram of resin. The reaction was carried out in an 
Erlenmeyer flask placed in a shaker for 36 hat room temperature. Following reaction 
washing with methylene chloride and drying, the resin was stored in the freezer. 
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Scheme 7: Conversion ofFMOC-leu to cesium salt. 
Nal,DMF 
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solution at RT (Scheme 7); the salt was then coupled to the chlorinated resin via Nal in 
DMF over 24 h (Scheme 8). The resin was then washed with DMF (2 x 50 mL), 
CH2Cl2 (2 x 50 mL), MeOH (2 x 50 mL), and dried. At this point it was important to 
find out how much of the amino acid coupled onto the resin. Usually the resin is sent 
for elemental analysis; in this case, it was assumed that approx 50 % coupling took 
place and we proceeded to the next step. A 50:50 mixture of cyclohexylamine and 
DMF was used to soak the resin for 1 h to remove the FMOC group (Scheme 9). 
After several washings with DMF (50 mL), CH2Cl2 (50 mL), EtOH (50 mL), CH2Cl2 







Scheme 9: Deprotection ofFMOC group. 
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FMOC-Leu-Leu-resin. The last ~ steps (soaking m 50:50 mixture of 
cyclohexylamine/DMF and coupling with DCC) were repeated once more (Scheme 10) 
After washing with DMF (50 mL) and CH2Cl2 (50 mL) and overnight drying under 
vacuum, a ninhydrin test was performed on a small quantity of resin to determine the 
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Three solutions were prepared for the ninhydrin test; 1) 2 mL of 0.01 KCN 
dil. to 100 mL with pyridine; 2) 500 mg ninhydrin in 10 mL of n-BuOH; 3) 80 g 
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phenol in 20 mL n-BuOH. A small amount of resin was added to 3 test tubes and 3-4 
drops of each solution to each tube. The test tubes were heated in boiling water for 3-4 
min. Upon heating, the beads turned bluish - corresponding to approximately 80% 
coupling (this was the first test performed on the resin; usually, elemental analysis is 
performed after each step to determine the amount of coupling). The final step 
involved deprotection from the resin via 19: 1 TF A:anisole solution, followed by 
extractions with MeOH and ether. After drying, a dark brown residue was left. 
However, the 1H NMR did not show the correct product; and only a singlet at 2.0 ppm 
and small impurities between 3.5 - 4.5 ppm were seen. 
For the preparation of Cbz-blocked Leu with Merrifield resin the following 
outline was used: a) nitration of the resin; b) esterification of the resin with Cbz-Leu; 
c) removal of Cbz-group and coupling with a second Cbz-Leu; d) repeat of step c) and 
coupling with a third Cbz-Leu; e) cleavage of Cbz and peptide from the resin. The 
first step involved nitrating the resin by HNO3 at O °C for 2 h (Scheme 11), followed 
by a series of washes: 3: 1 dioxane/H2O (100 mL), 3: 1 dioxane/3N HCl (100 mL), 
polystyren◊cH,Cl + ► -ONO2 polystyren CH2Cl 
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Scheme 12: Esterification of the resin. 
H20 (300 mL, soaking for 2 h), dioxane (2 x 50 mL)MeOH (2 x 100 mL) and drying. 
The next step was esterification with equimolar amounts of TEA and Cbz-Leu at reflux 
in EtOAc (Scheme 12) for 48 h, followed by the addition of a TEA/EtOAc/glacial 
acetic acid solution with continued reflux for another 4 h. After washings with ethyl 
acetate, ethanol, water, methanol (2 x 50 mL) and drying, deprotection of the Cbz 
group was conducted as follows. A solution of 30% HBr in glacial acetic acid (Scheme 
13) was used to soak the resin for 5 h in the shaker, followed by washings with glacial 
acetic acid (2 x 50mL), ethanol (2 x 50 mL), DMF (2 x 50 mL) and neutralization by 
TEA in DMF. A coupling reaction between Cbz-Leu and DCC in DMF was tried 
Scheme 13: Deprotection of the Cbz group. 
Scheme 14: Coupling with Cbz-leu. 
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next (Scheme 14). It \Vas left in the shaker at RT for 18 h. then washed with DMF (50 
mL), EtOH (50 mL) and glacial acetic acid (50 mL) to remove DCU. The last two 
steps (deprotection of Cbz by 30% HBr solution and coupling with Cbz-Leu) were 
repeated once more followed by cleavage of the peptide from the resin. This step 
involved washing the resin in 30% HBr/EtOAc solution overnight, then with acetic 
acid, EtOH, DMF and 2N NaOH. The filtrate was treated with 20% HCl, extracted 
with EtOAc, and after drying a yellow liquid was obtained. Again, 1H NMR did not 
show the expected product. Only a doublet at 2.2 ppm corresponding to 7H was seen. 
For both procedures, we believe that the coupling steps were successful as indicated by 
the ninhydrin test. The reagents used in the deprotection steps however, were probably 
too harsh and could have decomposed the desired products. 
Since both solid phase procedures failed to give the expected Leu-Leu-Leu 
tripeptide, the synthesis of the native tripeptide was not attempted; instead, work was 
resumed on the synthetic pathways. 
Conclusion 
The native tripeptide acetyl-phenylglycine-l-leucine-l-tryptophan, methyl ester 
was synthesized as the "S" and "R" isomers 9a and 9b, to serve as the natural and 
unnatural model for the transition state analogue of phosphoramidon. The tripeptides 
were synthesized using solution methods and DCC as coupling reagent in a 52.3 % and 
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49. 2 % yields, respective! y. Several purification steps such as washings. tirturatiom 
and recrystallizations were nedeed to remove all of the by-product DCU and these 
manipulations account for the reduced yield. The tripeptides have similar features in 
the 1H and 13C NMR spectra: they show nearly identical chemical shifts with small 
changes in the 13C NMR. A COSY spectrum of the S isomer was taken and showed 
strong peak intensities along the diagonal; moreover, the cross-peaks indicate coupling 
between tryptophan's protons, methoxy-tryptophan protons and leucine's protons. 
A phosphorus analogue of acetyl-phenylglycine was also synthesized, and 
approaches toward the preparation of the phosphorus-substituted tripeptide were 
initiated. The phosphorus analogue of acetyl-phenylglycine was initially synthesized as 
a diastereomeric mixture (13 and 14) which could not be separated into its individual 
stereoisomers by conventional flash chromatography or GC. Efforts shifted toward 
modifying the diastereomeric mixture into compounds which could be easier separated 
as well as being suitable for coupling with the deprotected dipeptide to obtain the 
phosphorus-substituted tripeptide. Modifications included attempted thionation of the 
P=O, acetylation of the amino group, hydrolysis of one of the methoxy groups, 
dealkylation of a benzyl group and chlorination of a phosphonate ester. Only two 
steps, namely, dealkylation and hydrolysis were successful in converting the 
phosphonamidate diastereomer 13 into a stable phosphonate salt 22. This salt 
represents a phosphorus analogue of acetyl-phenylglycine. Attempts to hydrolyze the 
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salt to a monoacid or to chlorinate it were not successful. It was hoped that in this 
way the salt could be coupled to the deprotected dipeptide 8 to obtain the· desired 
phosphono TS analogue. 
Future studies could explore alternative routes for insertion of the analogue 22 
into the peptide backbone, to obtain the transition state analogue of phosphoramidon. 
When this will be achieved, we could enhance our understanding in two areas: a) on 
the effect that a phosphorus center substituting for a peptide carbonyl can have on the 
conformation and dynamics of a peptide backbone, and b) on the requirements of zinc-
containing enzymes The native tripeptides, 9a and 9b will serve as essential models for 
study in both areas, especially for comparison of enzyme interaction. 
CHAPTER ID 
EXPERIMENTAL SECTION 
General methods. Commercially available reagents were purchased from Aldrich 
Chemical Co., (Milwaukee, WI), Chemical Dynamics Co., (South Plainfield, NJ), and 
Sigma Chemical Co., (St. Louis MO). All solvents and reagents were purified when 
necessary by standard literature methods (Perrin et al., 1988). Moisture sensitive 
reactions were conducted under an argon atmosphere utilizing standard techniques 
(Brown et al., 1975). 
Melting points were determined on a Mel-Temp melting point apparatus and are 
uncorrected. Analytical thin layer chromatography (TLC) was conducted on E. Merck 
aluminum-backed, 0.2 mm silica gel TLC plates. Visualization was accomplished with 
an ultraviolet lamp and ninhydrin (5 % ninhydrin in ethanol), ammonium molybdate 
(2 % ammonium molybdate in 90: 10: 1 distilled water-concentrated sulfuric acid-eerie 
ammonium sulphate) and DBQ (0.5 % 2,6-dibromoquinone chlorimide in ethyl ether) 
stains with heat. Flash chromatography was performed with Kieselgel 60, 230-400 
mesh (Merck) (Still et al., 1978). Elemental analyses were performed by Midwest 
Microlab Ltd., Indianapolis, IN. 
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Proton (1 H), carbon (13C) and phosphorus (31 P) NMR spectra were taken at 300 
MHz, 75.7 MHz and 121.5 MHz using a Varian VXR 300 NMR instrument. The 
chemical shifts of the 1H NMR and 13C spectra were referenced to tertramethyl silane 
(TMS) (8 = 0.00 ppm). Chemical shifts of the 1H peaks are relative to the deuterated 
chloroform singlet (8 = 7.24 ppm) and 13C peaks are relative to the middle of the 
deuterated chloroform triplet (8 = 77.00 ppm). 31P NMR spectra were taken in 
deuterated solvents with phosphoric acid as an external standard in chloroform-d (8 = 
0.00 ppm). Infrared data (IR) were obtained on a Perkin-Elmer Model 1310 instrument 
in chloroform, methanol or ethyl acetate in a liquid cell. Rotation data were recorded 
on a Perkin-Elmer Model 241 Polarimeter (Na lamp) at room temperature in 
appropriate solvents (c = 100 x g/mL). 
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Part A: Synthes is of Phe-Leu-Trp Tripeptide 
N-Acetyl-l-phenylglycine 2a. (Hongo et al., 1981). /-Phenylglycine 1 (5.0 g, 
3.3 mmol) and 33.0 mL of lM NaOH solution were stirred vigorously and chilled to 0 
~C. Cold NaOH (6.66 mL, lM) and 0.31 mL of acetic anhydride were added and the 
mixture was checked for basicity. The intermittent addition of NaOH and acetic 
anhydride (same amounts) was repeated 4 more times while testing for alkalinity at 
each step. Stirring continued for 30 min and the solution was then acidified to pH 1 
with concentrated HCl and the solution allowed to crystallize at O °C overnight. White 
crystals were collected by filtration and washed with cold water. Recrystallization 
from water affords long, needle-like crystals. Yield: 74%. Melting point: 192-194 °C. 
[a]D24 = +203.87° (c 2.3, MeOH). 1H NMR (D2O): 8 1.99 (s, 3H), 5.43-5.46 (d, J 
= 7.6 Hz, lH), 7.31-7.44 (m, 5H), 8.45-8.47 (d, J = 7.5 Hz, lH). 13C NMR: 8 
22.9, 56.3, 127.1, 127.8, 128.4, 136.9, 169.2, 172.3. 
Cbz-l-Leucine 4. (Choudry, et al., 1980). /-Leucine 3 (2.624 g, 20.0 mmol) 
and sodium bicarbonate (4.2 g, 50.0 mmol) were dissolved in 25 mL of water and 15 
mL of a saturated NaHCO3 solution at room temperature using a magnetic stirrer. 
Carbobenzyloxy chloride (Cbz-Cl) was added dropwise over a period of 30 minutes. 
The reaction was monitored by TLC for loss of CBZ-Cl, and was left stirring 
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overnight. At completion. the reaction mixture was extracted once with '10 mL of 
diethyl ether and the aqueous layer was acidified to pH 3 with 20% HCl while· cooling 
and stirring. The resulting white precipitate was extracted into 45 mL of ethyl acetate 
(3 x 15 mL). The ethyl acetate layers were combined and dried over anhydrous 
magnesium sulfate for 1 h. The mixture was filtered and the solvent was removed in 
vacuo to afford Cbz-l-leucine which was in the form of a thick, pale-yellow oil. 
Purification by Kugelrohr distillation at 0.5 mm pressure yields 75.1 % . Rf = 0.16 
(MeOH:CHCl3, 1:9). Boiling point: 122 °C. [a]0 24 = -5.796° (c 2.45, EtOAc). 1H 
NMR (CDC13): o 0.87-0.95 (m, 6H), 1.53-1.70 (m, 3H), 4.39-4.40 (m, lH), 5.09-
5.13 (m, 2H), 5.23-5.26 (d, J = 8.5 Hz, lH), 7.31-7.32 (m, 5H), 10.51 (br, lH). 
13C NMR: o 21.7, 22.9, 24.8, 41.4, 52.4, 67.1, 128.0, 128.1, 128.4, 135.9, 156.0, 
177.7. 
l-Tryptophan, methyl ester 6. l-Tryptophan, methyl ester hydrochloride 5 
(5.0 g, 19.6 mmol) was dissolved in 40 mL of distilled THF. Triethylamine (2.74 g, 
19.3 mmol) was added, and the reaction was stirred for 20 minutes. The mixture was 
filtered through a frit with celite and the solvent was removed in vacuo. l-Tryptophan 
methyl ester was obtained in the form of light - yellow oil and was used directly in the 
next step without further purification. 
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Cbz-/-leucine-1-tryptophan, methyl ester 7. (Shiba et al._ 1974) C'bz-/-
leucine 4 (6.06 g, 22.9 mmol) and DCC (4.72 g, 22.9 mmol) were dissolved in 150 
mL of distilled methylene chloride and chilled to 0 °C. l-Tryptophan methyl ester 6 
from the prior step was added and the reaction mixture was stirred under argon 
atmosphere for 3 h at O 0C. The reaction was monitored by TLC for loss of starting 
material 6. At completion, the reaction mixture was filtered through a pad of Celite 
and the solvent was removed in vacuo to yield the crude product as a yellow, sticky oil. 
Purification by flash chromatography using diethyl ether resulted in a white solid. 
Yield: 49.9%. Rr = 0.52 (EtiO). Melting point: 67-68 °C. [a]0 24 = +23.6 (c 1.0, 
EtiO). H NMR (CDCl3): 8 0.86-0.88 (d, 6H), 1.23-1. 77 (m, 3H), 3.27-3.29 (d, 2H), 
3.65 (s, 3H), 4.22-4.28 (m, lH), 4.86-4.93 (m, 2H), 4.98-5.04 (m, 2H), 5.05-5.23 
(d, J = 8.6 Hz, lH), 6.67-6.70 (d, J = 1.6 Hz, lH), 6.93 (s, lH), 7.07-7.15 (m, 
6H), 7.28-7.32 (m, 5H), 7.48-7.50 (d, lH), 8.14 (br, lH). 13C NMR: 8 21.7, 22.8, 
24.5, 27.4, 41.5, 52.3, 52. 7, 53. 7, 66.8, 109.2, 111.3, 118.3, 119.4, 122.0, 123.2, 
127.9, 128.0, 128.4, 135.9, 136.2, 154.6, 156.1, 172.0, 172.2. 
l-Leucine-l-tryptophan, methyl ester 8. (Rambhav et al., 1976). Cbz-l-
leucine-l-tryptophan methyl ester 7 (2.0 g, 4.3 mmol) was dissolved in 30 mL of 
absolute ethanol and approximately 10.0 mg of palladium on activated carbon (10% 
Pd/C) was added under a blanket of argon gas. The reaction mixture was evacuated 
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under vacuum aspirator and exchanged for a hydrogen atmosphere and allowed to 
proceed overnight at RT. The reaction was checked by TLC. The next morning, at 
completion, the mixture was filtered through celite and the solvent was evaporated in 
vacuo. The crude product was used directly in the next step without further 
purification. 
(S)-N-acetyl-l-phenylglycine-l-leucine-l-tryptophan, methyl ester 9a. N-
Acetyl-l-phenylglycine (0.08 g, 0.43 mmol) and DCC (0.09 g, 0.43 mmol) were 
dissolved in 10 mL of distilled CH2Cl2 and stirred for 30-45 minutes at O 
0C. l-
Leucine-l-tryptophan, methyl ester 8 (0.20 g, 0.43 mmol) was added and the reaction 
mixture was stirred under an argon atmosphere for 4 hours at O °C, then at RT 
overnight. The solution was filtered through a pad of Celite and neutralized to pH 8-9 
by the dropwise addition of 5 % NaHCO3 • After the organic phase was dried over 
anhydrous magnesium sulfate, it was evaporated in vacuo to obtain a solid, yellow 
residue. The solid was washed 3-4 times with hot CH2Cl2 to remove DCU then air 
dried. The solid was redissolved in 20 mL EtOAc and washed with 20% HCl (2 x 10 
mL), 10% NaOH (2 x 20 mL) and brine. The solution was dried over Na2SO4 , filtered 
and concentrated to a solid. Recrystallization (3x) from CH2Cli/EtiO afforded white, 
powdery crystals. Yield: 52.3 % . Rf = 0.20 (EtOAc:CH2Cl2 9: 1). Melting point: 
178-180 °C. [a]n24 = + 44.4 (c 0.9, CHC13). 1H NMR: o 0.34-0.58 (d,lH), 0.68-
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0.73 (d. 1H). 0.81-0.87 (m. 4H). 1.50-1.55 (m. 3H). 1.96 (s. 3H). 3.14-3.24 (2d. 
2H), 3.67 (s, 3H), 4.71-4.80 (m, lH), 4.80-4.87 (m, lH), 5.0-5.1 (m, lH), 5."88-5.90 
(d, lH), 6.78-6.79 (d, lH), 7.02-7.63 (m, lOH), 7.98 (s, lH). 13C NMR: 8 22.1, 
22.6, 22.9, 24.7, 27.4, 41.3, 52.0, 52.3, 52.8, 56.7, 109.5, 111.3, 118.2, 119.4, 
122.0, 123.1, 126.9, 127.1, 127.3, 128.3, 128.8, 129.0, 135.9, 137.8, 169.9, 170.2, 
171.1, 171.9. Anal. calcd. for C28H34N4O5 · 1.5 H2O: C, 63.02; H, 6.61; N, 10.50. 
Found: C, 63.14; H, 6.57; N, 10.43. 
(R)-N-acetyl-d-phenylglycine-l-leucine-l-tryptophan, methyl ester 9b. N-
Acetyl-d-phenylglycine (0.08 g, 0.43 mmol) and DCC (0.09 g, 0.43 mmol) were 
dissolved in 10 mL of distilled CH2Cl2 and stirred for 30-45 minutes at O 0C. l-
Leucine-l-tryptophan, methyl ester 8 (0.20 g, 0.43 mmol) was added and the reaction 
mixture was stirred under an argon atmosphere for 4 hours at O 0c, then at RT 
overnight. The solution was filtered through a pad of Celite and neutralized to pH 8-9 
by the dropwise addition of 5 % NaHCO3. After the organic phase was dried over 
anhydrous magnesium sulfate, it was evaporated in vacuo to obtain a solid, yellow 
residue. The solid was washed 3-4 times with hot CH2 Cl2 to remove DCU, then air 
dried. The solid was redissolved in 20 mL EtOAc and washed with 20% HCl (2 x 10 
mL), 10% NaOH (2 x 20 mL) and brine. The solution was dried over NazSO4, filtered 
and concentrated to a solid. Recrystallization (3x) from CH2Clz1EtzO afforded white, 
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powdery crystals. Yield: 49.6 % . R1 = 0.22 (Et0Ac:CH 2C1 2 9: 1). Melting point· 
176-178 °c. 1NMR: o 0.51-0.58 (d, lH), 0.62-0.69 (d, lH), 0.79-0.81 (m, 4H), 
1.52-1.68 (m, 3H), 1.94 (s, 3H), 3.10-3.21 (2d, 2H), 3.63 (s, 3H), 4.55-4.59 (m, 
lH), 4.66-4.75 (m, lH), 4.91-5.01 (m, lH), 5.77-5.86 (d, lH), 6.74-6.78 (d, lH), 
6.98-7.33 (m, lOH), 7.87 (s, lH). 13C NMR: o 19.8, 20.1, 21.4, 22.3, 23.9, 40.4. 
51.8, 52.2, 52.4. 56.3, 109.8, 111.7, 118.3, 119.8, 121.9, 122.7, 124.1, 127.1, 
128.1, 128.5, 128.8, 136.1, 138.2, 170.1, 171.3, 171.6, 172.0. 
Part B: Synthesis of Phosphonamidate Compounds 
(R,S)-Dimethyl-N-(S)-( a-methylbenzyl)-a-aminobenzyl phosphonate 13. 
Method A. Benzaldehyde (2.15 mL, 24.75 mmol), (S)-(-)-a-methyl benzyl amine 
(3.19 mL, 24.75 mmol), toluene (50 mL) and p-toluene sulfonic acid (cat. amt.) were 
brought to gentle reflux using a Dean-Stark condenser and maintained for 3 h. When 
the water volume in the collector remained constant and the reaction solution turned 
clear, the reaction was stopped and cooled to RT. Dimethyl phosphite (2.29 mL, 
0.025 mol) was added and the solution was refluxed for 4 hours, then stirred slowly, at 
RT overnight. The solvent was removed, and the remaining yellow oil was dissolved 
in diethyl ether (60 mL) and washed with 20% HCl solution (70 mL). The aqueous 
layer was neutralized to pH 7 by the cautious addition of NaOH pellets at O 0c then 
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extracted with EtOAc (1 x 25 mL). A solid formed upon evaporation that was purified 
by flash chromatography (chloroform/diethyl ether/pet ether; 3:3:4). The product was 
collected as a mixture of diastereomers and to date could not be separated by 
chromatographic methods. Yield: 86%. Rr = 0.24 (diethyl ether). Melting point: 74-
76 °C. [a]0 24 = -37.88 (c 2.5, MeOH). 1H NMR: 8 1.30-1.32 (d, J = 6.35 Hz, 3H), 
2.21 (br, lH), 3.41-3.46 (dd, J = 10.3 Hz, 3H), 3.71-3.86 (q, J = 10.l Hz, lH), 
4.08-4.14 (d, J = 20.17 Hz, lH), 7.24-7.32 (m, lOH). 13C NMR: 8 22.14, 53.26 and 
53.35 (chiral C), 53.61 and 53.70 (chiral C), 56.63, 58.65, 126.45, 126.72, 126.86, 
126.97, 127.59, 127.63, 128.0, 128.10, 128.20, 128.26, 128.29. 31 P NMR: 8 27.2, 
27.5. Anal. calcd. for C17H22NO3P: C, 63.94; H, 6.95; N, 4.39. Found: C, 63.87; 
H, 6.97; N, 4.39. 
Method B. A mixture of benzaldehyde (2.03 mL, 0.02 mol), anhydrous 
potassium carbonate (4.0 g) and (S)-(-)-a-methyl benzyl amine toluene (60 mL) was 
heated on a steam bath for 10 min, then cooled to RT. Toluene was removed, 
potassium carbonate was filtered off and the residue was refluxed with diethyl 
phosphite (2.57 mL, 0.02 mol) or dimethyl phosphite (1.83 mL, 0.02 mol) at 120-140 
°C for 30 min. After cooling to RT, the remaining oil was dissolved in diethyl ether 
(60 mL) and washed with 20% HCl solution (70 mL). The aqueous layer was 
neutralized with NaOH pellets then washed with EtOAc (2 x 25 mL). The organic 
67 
layers were combined and dried ro afford a yellowish oil which was purified by flash 
column chromatography using ether as a solvent. Yield 13: 30. 7 % ; 14: 50.2 % . The 
1H NMR and melting point were identical to those obtained from method A. 
Method C. Benzaldehyde (1.38 mL, 0.014 mol), toluene (20 mL), (S)-(-)-a-
methyl benzylamine (1.76 mL, 0.014 mol) and magnesium sulfate (4.0 g) were stirred 
at RT for 3 hr under Ar gas. Dimethyl phosphite (1.25 mL, 0.014 mol) was added and 
the reaction was stirred at RT overnight. TLC did not indicate complete product 
formation, so the solution was refluxed for 4 h or until all starting material was 
consumed. Workup was the same as for the previous procedures. Yield:13: 29.3%. 
(reaction with 14 was not conducted). The 1H NMR and melting point were identical 
to those obtained from method A. 
(R,S)-Diethyl-N-(S)-(a-methylbenzyl)-a-aminobenzyl phosphonate 14. 
Method A. Benzaldehyde (2.15 mL, 24.75 mmol), (S)-(-)-a-methyl benzylamine (3.19 
mL, 24.75 mmol), toluene (50 mL) and p-toluene sulfonic acid (cat. amt.) were 
brought to gentle reflux using a Dean-Stark condenser and maintained for 3 h. When 
the water volume in the collector remained constant and the reaction solution turned 
clear, the reaction was stopped and cooled to RT. Diethyl phosphite (3.22 mL, 0.025 
mol) was added and the solution was refluxed for 4 hours, then stirred at RT overnight. 
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The solvent was removed. and the remaining yellow oil was dissolved in diethyl ether 
(60 mL) and washed with 20% HCl solution (70 mL). The aqueous layer was 
neutralized to pH 7 by NaOH pellets in an ice bath then extracted with EtOAc (2 x 25 
mL). The combined organic layers were concentrated to a yellow oil, which was 
purified by flash chromatography (chloroform/diethyl ether/pet ether; 3:3:4). The 
product was collected as a mixture of diastereomers and so far could not be separated 
by chromatographic methods. Yield: 89.29%. Rr = 0.12 (3:3:4 CHC13:ether:pet. 
ether). Melting point: 38-40 °C. [a]0 24 = -35.01 (c 2.6, MeOH). 1H NMR: D 1.06-
1.10 (m, 3H), 1.28-1.33 (m, 6H), 2.21 (br, lH), 3.67-3,76 (m, 2H), 4.05-3.85 (m, 
lH), 4.06-4.19 (m, 3H), 7.21-7.32 (m, IOH). 13C: D 16.46, 16.54, 22.32, 55.27, 
57.13, 59.14, 62.88, 126.72, 127.0, 127.07, 128.32, 128.35, 128.38, 128.41, 128.53. 
31P NMR: D 24.35, 24.76. Anal. calcd. for C19H26NO3P: C, 65.69; H, 7.55; N, 4.03. 
Found: C, 65.64; H, 7.61; N, 4.10. 
(R,S)-Dimethyl-N-benzyl-a-aminobenzyl phosphonate 19. The procedure 
used to synthesize 13 and 14 was used here except that benzylamine was substituted for 
(S)-(-)-a-methylbenzylamine. Purification by column chromatography 
(chloroform/diethyl ether/pet ether; 3:3:4) afforded a clear oil which solidified in the 
refrigerator. Yield: 76.6%. Rr = 0.15 (chloroform/diethyl ether/pet ether 3:3:4). 
Melting point: 30-32 °C. 1H NMR: D 2.09 (br, lH), 3.50-3.54 (d, J = 11.39 Hz, 
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3H), 3.69-3.73 (d, J = 11.42 Hz. 3H). 3.99-4.06 (d. J = 20.02 Hz. 1H). 13c' NMR: 
8 50.99, 53.67, 58.22, 60.26, 127.14, 128.01, 128.06, 128.31, 128.36, . 128.52, 
128.57, 128.61. 31 P NMR: 8 26.47. Anal. calcd. for C16H20NO,P: C, 62.94: H. 
6.60; N, 4.59. Found: C, 62.82; H, 6.64; N, 4.70. 
(R,S)-Dimethyl-a-aminobenzyl phosphonate 20. Compound 13 (1.234 g, 
3.87 mmol) was first dissolved in 14 mL MeOH and 0.25 g of palladium on activated 
carbon (10% Pd/C) and 0.4 mL CF3COOH were added and the mixture was placed in 
a Paar hydrogenator (H2 , 45 psi) for 3 h. Upon completion, the solution was filtered 
through Celite, evaporated to a yellow oil, neutralized by NaHCO3 and extracted into 
ethyl acetate (2 x 15 mL). The combined organic layers were concentrated to a yellow 
oil which was purified by flash chromatography (CHCl3:MeOH:Hexanes 85: 10:5). 
Yield: 90.6%. Rr = 0.18 (CHCl3:MeOH:Hexanes 85:10:5). 1H NMR: 8 1.96 (br, 
2H), 3.57-3.60 (d, J = 11.34 Hz, 3H), 3.70-3.73 (d, J = 11.37 Hz, 3H), 4.27-4.31 
(d, J = 17.34 Hz, lH), 7.33-7.47 (m, 5H). 13C NMR: 8 29.66, 52.86, 54.86, 
127.57, 127.65, 127.93, 127.97, 128.53, 128.56, 136.61. 31P NMR: 8 26.37. 
Note: This reaction also takes place at ambient H2 pressure but it requires 5 h for 
completion. 
(R,S)-Dimethyl-a-acetylaminobenzyl phosphonate 21. Compound 20 (0.123 
70 
g, 0. 75 mmol) was dissolved in methylene chloride (5 ml) at RT. Acetyl ch10ride 
(0.08 mL, 2 eq) was added slowly and the reaction was allowed to proceed for 1 h 
when TLC indicated consumption of starting material. (It was noted that shortly after 
the addition of acetyl chloride the solution turns milky). The solvent was evaporated 
and the mixture was neutralized by NaHCO3 to pH 7 and extracted with ethyl acetate (3 
x 10 mL). After drying over Na2SO4 and removal of solvent a pale yellow solid 
remains. Recrystallization from CHC13/pet. ether and a few drops of ether afords white 
crystals. Yield: 51.35% Rr = 0.25 (10% MeOH/EtOAc). Melting point: 136-138 
~C. 1H NMR: 8 1.92 (s, 3H), 3.34-3.38 (d, J = 10.55 Hz, 3H), 3.71-3.74 (d, J = 
10.74 Hz, 3H), 5.45-5.60 (q, J = 9.47 Hz, lH), 7.20-7.45 (m, 5H), 7.65-7.70 (m, J 
= 9.03 Hz, lH). 13C NMR: 8 22.86, 48.88, 50.50, 53.76, 128.20, 128.25, 128.28, 
128.65, 128.68, 134.88, 170.0 31 P NMR: 8 24.63. Anal. calcd. for C11 H16NO4P: C, 
51.36; H, 6.27; N, 5.45. Found: C, 51.32; H, 6.24; N, 5.39. 
(R,S)-Methyl-a-acetaminobenzyl phosphonate sodium salt 22. Compound 
21 (0.187 g, 0. 73 mmol) was dissolved in absolute ethanol (3 mL) at RT. One 
equivalent of IM NaOH solution (0.73 mL) was added and the solution was stirred ar 
RT under Ar overnight. The reaction was checked by TLC and the following day, 
TLC indicated complete consumption of starting material. The solvent was removed 
under vacuum, and the residue was washed with absolute ethanol (3 x 2 mL). The 
71 
remaining white compound was dried under vacuum overnight. Yield: 90o/c. R = on 
the baseline (10% MeOH/CHC13). Melting point: 1H NMR: b 1.88 (s, 3H), 3.34-
3.37 (d, 3H), 5.92-6.02 (d, lH), 7.22-7.24 (m, 5H). 31 P NMR: b 17.93 ppm. 
Methyl hydrogen-N-(S)-a-methylbenzyl-a-aminobenzyl-(R,S) phosphonic 
acid 26. To compound 13 (0.200g, 0.63 mmol) were added to 1 mL of 1 M NaOH 
and 4 mL of absolute ethanol and the reaction was refluxed for 5 h. At completion, the 
solution was cooled to RT, acidified to pH 3 by 0.75 ul of 20% HCl, and extracted 
three times with 6 mL of isopropanol:chloroform (1:9). The organic layers were 
combined and dried over Na2SO4 • The drying agent was filtered off, and removal of 
the solvent gave a white residue which was recrystallized from water. Yield: 74.2 % . 
Rt= 0.29 (MeOH:CHCl3 1:9). Melting point: 189-191 °C. [a]0 24 = -17.26 (c 1.0, 
D2O). 
1H NMR: b 1.51-1.54 (d, J = 7.0 Hz, 3H), 3.31-3.35 (d, J = 9.9 Hz, 3H), 
4.13-4.18 (d, J = 15.7 Hz, lH), 4.50-4.51 (q, lH), 7.22-7.35 (m, lOH). 13C NMR: 
b 22.4, 56.53, 56.62, 60.82, 131.93, 132.94, 133.02, 133.48, 133.61, 133.91, 
134.02, 139.97. 31 P NMR: b 12.34, 12.55. Anal. calcd. for C16H20NO3P: C, 62.94; 
H, 6.60; N, 4.59. Found: C, 62.81; H, 6.64; N, 4.53. 
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